EGFR activation limits the response of liver cancer to lenvatinib

Hepatocellular carcinoma (HCC)—the most common form of liver cancer—is an aggressive malignancy with few effective treatment options 1 . Lenvatinib is a small-molecule inhibitor of multiple receptor tyrosine kinases that is used for the treatment of patients with advanced HCC, but this drug has only...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature (London) 2021-07, Vol.595 (7869), p.730-734
Hauptverfasser: Jin, Haojie, Shi, Yaoping, Lv, Yuanyuan, Yuan, Shengxian, Ramirez, Christel F. A., Lieftink, Cor, Wang, Liqin, Wang, Siying, Wang, Cun, Dias, Matheus Henrique, Jochems, Fleur, Yang, Yuan, Bosma, Astrid, Hijmans, E. Marielle, de Groot, Marnix H. P., Vegna, Serena, Cui, Dan, Zhou, Yangyang, Ling, Jing, Wang, Hui, Guo, Yuchen, Zheng, Xingling, Isima, Nikita, Wu, Haiqiu, Sun, Chong, Beijersbergen, Roderick L., Akkari, Leila, Zhou, Weiping, Zhai, Bo, Qin, Wenxin, Bernards, René
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!